Notably, TGF-Beta pathway genes such as SMAD2, SMAD4, and TGFBR2 displayed differential mutation frequencies in all three cancers, suggesting a recurring pattern of dysregulation in this pathway among H/L patients. This evidence concerns the gene TGFB1 and cancer.